These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 27342744)
1. Impact of Treatment with Naloxegol for Opioid-Induced Constipation on Patients' Health State Utility. Lawson R; King F; Marsh K; Altincatal A; Cimen A Adv Ther; 2016 Aug; 33(8):1331-46. PubMed ID: 27342744 [TBL] [Abstract][Full Text] [Related]
2. A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation. Webster L; Tummala R; Diva U; Lappalainen J J Opioid Manag; 2016; 12(6):405-419. PubMed ID: 28059433 [TBL] [Abstract][Full Text] [Related]
3. Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation. Webster L; Diva U; Tummala R; Sostek M Pain Pract; 2018 Apr; 18(4):505-514. PubMed ID: 28898536 [TBL] [Abstract][Full Text] [Related]
4. Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK. Lawson R; Ryan J; King F; Goh JW; Tichy E; Marsh K Pharmacoeconomics; 2017 Feb; 35(2):225-235. PubMed ID: 27663572 [TBL] [Abstract][Full Text] [Related]
5. Naloxegol for the treatment of opioid-induced constipation. Tack J; Corsetti M Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):855-61. PubMed ID: 25220391 [TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation. White WB; Kowey P; Diva U; Sostek M; Tummala R J Cardiovasc Pharmacol Ther; 2018 Jul; 23(4):309-317. PubMed ID: 29504415 [TBL] [Abstract][Full Text] [Related]
7. Naloxegol: treatment for opioid-induced constipation in chronic non-cancer pain. Leonard J; Baker DE Ann Pharmacother; 2015 Mar; 49(3):360-5. PubMed ID: 25471070 [TBL] [Abstract][Full Text] [Related]
8. Naloxegol for opioid-induced constipation in patients with noncancer pain. Chey WD; Webster L; Sostek M; Lappalainen J; Barker PN; Tack J N Engl J Med; 2014 Jun; 370(25):2387-96. PubMed ID: 24896818 [TBL] [Abstract][Full Text] [Related]
9. Naloxegol: the first orally administered, peripherally acting, mu opioid receptor antagonist, approved for the treatment of opioid-induced constipation. Corsetti M; Tack J Drugs Today (Barc); 2015 Aug; 51(8):479-89. PubMed ID: 26380386 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response. Tack J; Lappalainen J; Diva U; Tummala R; Sostek M United European Gastroenterol J; 2015 Oct; 3(5):471-80. PubMed ID: 26535126 [TBL] [Abstract][Full Text] [Related]
11. Randomised clinical trial: the long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. Webster L; Chey WD; Tack J; Lappalainen J; Diva U; Sostek M Aliment Pharmacol Ther; 2014 Oct; 40(7):771-9. PubMed ID: 25112584 [TBL] [Abstract][Full Text] [Related]
12. ▼Naloxegol for opioid-induced constipation. Drug Ther Bull; 2015 Dec; 53(12):138-40. PubMed ID: 26660436 [TBL] [Abstract][Full Text] [Related]
13. Naloxegol to Treat Constipation in a Patient Taking Opioids for Cancer Pain: A Case Report. Gálvez R; Maire C; Tovar I; Vargas P A A Pract; 2018 Jul; 11(1):22-24. PubMed ID: 29634552 [TBL] [Abstract][Full Text] [Related]
14. Naloxegol , a new drug for the treatment of opioid-induced constipation. Corsetti M; Tack J Expert Opin Pharmacother; 2015 Feb; 16(3):399-406. PubMed ID: 25496063 [TBL] [Abstract][Full Text] [Related]
15. Population Exposure-Response Modeling of Naloxegol in Patients With Noncancer-Related Pain and Opioid-Induced Constipation. Al-Huniti N; Nielsen JC; Hutmacher MM; Lappalainen J; Cantagallo K; Sostek M CPT Pharmacometrics Syst Pharmacol; 2016 Jul; 5(7):359-66. PubMed ID: 27435972 [TBL] [Abstract][Full Text] [Related]
16. Naloxegol: A Novel Therapy in the Management of Opioid-Induced Constipation. Jones R; Prommer E; Backstedt D Am J Hosp Palliat Care; 2016 Nov; 33(9):875-880. PubMed ID: 26150678 [TBL] [Abstract][Full Text] [Related]
17. Naloxegol: a review of its use in patients with opioid-induced constipation. Garnock-Jones KP Drugs; 2015 Mar; 75(4):419-25. PubMed ID: 25666542 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use. Nalamachu S; Gudin J; Datto C; Coyne K; Poon JL; Hu Y J Opioid Manag; 2018; 14(3):211-221. PubMed ID: 30044486 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis. Cobo Dols M; Beato Zambrano C; Cabezón Gutiérrez L; Chicas Sett R; Blancas López-Barajas MI; García Navalón F; Fírvida Pérez JL; Serrano Bermúdez G; Togores Torres P; Delgado Mingorance I; Giraldo Marín A; Librán Oriol A; Paredes Lario A; Sánchez Mauriño P; Higuera Gómez O; Moreno Muñoz D; Jiménez López AJ; Huerta González I; Sanz Yagüe A; Soler López B BMJ Support Palliat Care; 2021 Mar; 11(1):25-31. PubMed ID: 32376758 [TBL] [Abstract][Full Text] [Related]
20. Population Exposure-Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid-Induced Constipation. Al-Huniti N; Xu H; Zhou D; Aksenov S; Fox R; Bui KH CPT Pharmacometrics Syst Pharmacol; 2017 Oct; 6(10):705-711. PubMed ID: 28782266 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]